Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging violations of federal securities laws due to false and misleading statements regarding the company's business and prospects [1][6]. Company Overview - MoonLake Immunotherapeutics is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), particularly in dermatology and rheumatology [4]. - The company's sole drug candidate, sonelokimab (SLK), is primarily developed for hidradenitis suppurativa (HS) and also targets psoriatic arthritis, psoriasis, and axial spondyloarthritis [4]. Clinical Development - MoonLake began its Phase 2b MIRA trial of sonelokimab in May 2022, reporting positive top-line results in June 2023, achieving its primary HiSCR75 endpoint [5]. - Follow-up data in October 2023 indicated further improvement with continued treatment, and both the FDA and EMA endorsed the proposed Phase 3 program, which began patient screening in May 2024 [5]. Allegations and Stock Impact - The lawsuit claims that throughout the class period, the defendants made false statements regarding the efficacy of SLK compared to traditional monoclonal antibodies, including claims about molecular targets and clinical benefits [6]. - On September 28, 2025, MoonLake announced that SLK failed to demonstrate competitive efficacy relative to the traditional monoclonal structure BIMZELX, leading to a significant stock price drop of $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [7].

BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 10, 2025, to report its financial results for the second quarter ended September 30, 2025, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” ...

Avidity Biosciences, Inc. (NASDAQ:RNA) stock surged after announcing a $12 billion all-cash acquisition by Novartis AG (NYSE:NVS), marking one of the largest biotech buyouts of the year.Analyst Downgrade Matches $72 Per Share OfferH.C. Wainwright analysts led by Ananda Ghosh downgraded Avidity Biosciences to Neutral from Buy and set a $72 price forecast, matching the cash offer from Novartis AG.The analysts’ move follows Avidity’s announcement that it will be acquired by Novartis for $72 per share, valuing ...

Core Insights - Halozyme Therapeutics (HALO) is set to report its third-quarter 2025 results on November 3, with sales and earnings estimates at $336.9 million and $1.62 per share respectively [1][7] - Earnings estimates for 2025 have risen from $6.01 to $6.18 per share over the past 60 days [1] Earnings Performance - Halozyme has a strong history of earnings surprises, having exceeded earnings expectations in the last four quarters with an average surprise of 19.74% [2][3] - The most recent quarter saw an earnings surprise of 25.20% [2] Earnings Prediction Model - The company's earnings prediction model indicates a likely earnings beat, supported by a positive Earnings ESP of +2.53% and a Zacks Rank of 3 (Hold) [4][5] Revenue Drivers - The anticipated revenue for Q3 2025 is expected to be bolstered by royalty gains from partnerships with Roche, J&J, and argenx [7][9] - Halozyme's collaboration agreements with large pharmaceutical companies utilizing its ENHANZE technology are key revenue contributors, generating royalties, milestone payments, and annual license fees [8] Recent Developments - Halozyme has entered into an agreement to acquire Elektrofi for $750 million, which is expected to enhance its drug delivery technology and support long-term revenue growth [11][12] - The company reaffirmed its 2025 revenue guidance, expecting total revenues between $1.28 billion and $1.36 billion, with royalty revenues projected at $825-$860 million [13] Stock Performance and Valuation - Year-to-date, Halozyme's shares have increased by 38.4%, outperforming the industry and the S&P 500 [14] - The stock is currently trading at a price-to-sales ratio of 6.97, which is above the industry average of 2.26 but below its five-year mean of 8.41 [16] Financial Position - Halozyme maintains a strong financial position with $548 million in cash and no near-term debt, providing sufficient liquidity for operations [17] Growth Potential - The company is expected to benefit from higher royalties and incremental contributions from proprietary products, alongside the diversification from the Elektrofi acquisition [18] - Analysts have a positive outlook on the stock, reflected in rising earnings estimates [20]

JHVEPhoto / Getty Images Avidity Biosciences is being bought by Novartis in a $12 billion deal. Key Takeaways Novartis is buying Avidity Biosciences in an all-cash deal valued at $12 billion to access Avidity's experimental treatments for neuromuscular diseases. The purchase price of $72 per share is a 46.5% premium to Avidity's closing price Friday. Avidity stock was up more than 40% in midday trading Monday, as were shares of Dyne Therapeutics, which is also developing RNA therapies for neuromuscul ...

First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its recent attendance at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The Conference, held October 22-26, 2025, in Boston, ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented posters at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics highlighting preclinical data that further illustrate the potential for ORIC-944, a potent and selective allosteric inhibitor of the polycomb repressive comple ...

CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall SurvivalFLORHAM PARK, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the U.S. Food and Drug Administration (FDA) has granted rare pediatric drug designation ( ...

MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors ...

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the immediate exercise of warrants, previously issued in March and August 2024 (the “Existing Warrants”), to purchase up to 22,363,714 shares of its common stock for gross cash proceeds of approximately $31.0 million. In consideration for th ...